TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23690342
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blocker treatment
Study: 20427734
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (45 mg zinc/d as gluconate for 6 months)
Study: 18987396
Drug: Topical hemostasis
Normalized name: collagen hemostat Topical Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical hemostasis patch (SafeSeal Patch, Possis Medical Inc.) with manual pressure
Study: 16635793
Drug: Thymoglobulin (THY)
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin (THY) 4.5 to 6.0 mg/kg
Study: 12825855
Drug: Fulvestrant 250
Normalized name: fulvestrant 250 MG in 5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant 250 mg as a monthly intramuscular injection followed by subsequent endocrine therapy
Study: 12825855
Drug: Subsequent endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent endocrine therapy after no clinical benefit from fulvestrant
Study: 11023930
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection of 5 mg of P5 variant
Study: 11023930
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus injection of 2.5 mg of P10 variant
Study: 8828024
Drug: Ebastine 10mg
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 10mg once daily
Study: 8828024
Drug: Terfenadine 60mg
Normalized name: TERFENADINE 60MG TAB
DrugBank: Terfenadine (DB00342)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terfenadine 60mg twice daily
Study: 21492763
Drug: MitraClip treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MitraClip treatment
Study: 28973174
Drug: Low-dose alteplase
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alteplase
Study: 28973174
Drug: Standard-dose alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose alteplase
Study: 23575879
Drug: Oral omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral omega-3 fatty acids supplements for 12 weeks
Study: 22594137
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg twice daily)
Study: 22594137
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose pill twice daily)
Study: 18301124
Drug: quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: quetiapine XR (once-daily equivalent dose)
Study: 18301124
Drug: quetiapine IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: quetiapine IR (twice-daily)
Study: 10699894
Drug: Chemotherapy based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy based on the combination of cisplatin and etoposide
Study: 10699894
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and PC resection
Study: 9068554
Drug: Gastrointestinal lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrointestinal lavage solution (3 L)
Study: 8403120
Drug: Parenteral analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral analgesia with morphine
Study: 31931550
Drug: Chemoprophylaxis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoprophylaxis with 2.5 mg fondaparinux for 5 days postoperatively
Study: 29575241
Drug: Supported self‐management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supported self‐management delivered by diabetes specialist nurses plus treatment as usual
Study: 21189774
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 mg/kg) and submucosal fentanyl (3 microg/kg)
Study: 21189774
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 mg/kg) and submucosal placebo
Study: 12707646
Drug: Active antigenic
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active antigenic suspension
Study: 8823335
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus pamidronate 45 mg in 250 mL of saline as a 1‐hour intravenous infusion every 3 weeks
Study: 8823335
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus pamidronate
Study: 1418071
Drug: Pirenzepine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (100 mg/d)
Study: 3965269
Drug: Domperidone (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (chronic administration, 35‐51 days)
Study: 30021756
Drug: Natural S-equol
Normalized name: S-equol
DrugBank: Equol (DB11674)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural S-equol supplement (10 mg a day, orally, twice daily for three menstrual cycles)
Study: 30021756
Drug: Placebo (orally,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (orally, twice daily for three menstrual cycles)
Study: 25633713
Drug: Low-dose CpG-B
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CpG-B + GM-CSF
Study: 28972083
Drug: Low-dose CpG-B
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CpG-B
Study: 22985432
Drug: dexpramipexole 300
Normalized name: Dexpramipexole
DrugBank: Dexpramipexole (DB15130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexpramipexole 300 mg/day
Study: 22985432
Drug: dexpramipexole 50
Normalized name: Dexpramipexole
DrugBank: Dexpramipexole (DB15130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexpramipexole 50 mg/day
Study: 18239661
Drug: Methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate hydrochloride (MPH) 0.5 mg/kg
Study: 16357400
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (fixed-duration injection protocol, 38 sec duration)
Study: 16357400
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (fixed-rate injection protocol, 3 or 4 mL/sec)
Study: 16357400
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (fixed-duration injection protocol, 47 sec duration)
Study: 3009368
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of irradiation
Study: 31439367
Drug: Uncemented press-fit
Normalized name: garden cress sprout extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncemented press-fit Regenerex® Porous Titanium Construct tibial tray and matching cemented patella and femoral components (hybrid implant)
Study: 28056024
Drug: Single-dose 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose 400 mg albendazole
Study: 23908568
Drug: Bevacizumab (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (2.5 mg)
Study: 23908568
Drug: Ranibizumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab (1 mg)
Study: 11351141
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors (ChE‐Is) including donepezil
Study: 8195995
Drug: Composite resin‐glass
Approvals — FDA: no, EMA: no, PMDA: no
Description: Composite resin‐glass ionomer hybrid with a dentinal bonding agent
Study: 3370922
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg of alpha‐methyldopa
Study: 3370922
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of alpha‐methyldopa
Study: 10952746
Drug: Radon and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radon and carbon dioxide baths (1.3 kBq/l, 1.6 g carbon dioxide/l on average)
Study: 8828098
Drug: Endotoxin administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endotoxin administration (Escherichia coli, Lot EC‐5, 4 ng/kg)
Study: 8828098
Drug: Antiendotoxin molecules
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiendotoxin molecules
Study: 8828098
Drug: Mediator receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mediator receptor antagonist
Study: 8828098
Drug: Antimediator therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimediator therapy
Study: 271585
Drug: Anti-inflammatory agents
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory agents
Study: 1580285
Drug: Perindopril (4-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4-8 mg/day)
Study: 6342352
Drug: Metoprolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (15 mg intravenously followed by 200 mg daily orally for 3 months)
Study: 30833491
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (250 mg at anesthetic induction and 250 mg at initiation of cardiopulmonary bypass)
Study: 28685884
Drug: Recent Injection
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recent Injection Drug Use (IDU)
Study: 25187158
Drug: Biological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological treatment (specifics not provided)
Study: 23981692
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid 1 g 10‐min bolus followed by 1 g eight‐hour infusion
Study: 15063813
Drug: Pamidronate (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (30 mg per treatment) given at 3-month intervals for 12 months
Study: 11590925
Drug: Triple-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple-drug regimen with abacavir
Study: 11590925
Drug: PI-containing triple-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI-containing triple-drug combinations
Study: 8149030
Drug: Single 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 1.5 gram dose of cefuroxime plus three doses of placebo
Study: 8149030
Drug: Four 1
Normalized name: Wal-Four 1% Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 1 gram doses of cefazolin
Study: 25117066
Drug: PK-guided 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PK-guided 5-FU dosing
Study: 22985896
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine gel (CLX)
Study: 15830986
Drug: Intradiscal ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradiscal ozone injection
Study: 15830986
Drug: Microdiscectomy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdiscectomy and Intradiscal ozone injection
Study: 10348358
Drug: Alpha-adrenergic blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-adrenergic blocking agent (phentolamine mesylate, 20 ml infused at 2 ml/min)
Study: 10348358
Drug: Placebo (physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (physiological saline, 20 ml infused at 2 ml/min)
Study: 1940488
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral morphine in fasted state
Study: 1940488
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral morphine in fed state
Study: 26313229
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg BR-DIM, twice daily
Study: 26313229
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg BR-DIM, twice daily
Study: 26313229
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily
Study: 26313229
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg BR-DIM, twice daily
Study: 15144473
Drug: Myrmecia pilosula
Normalized name: Codonopsis pilosula root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myrmecia pilosula ant venom immunotherapy (VIT)
Study: 26054104
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis in UHR
Study: 21321152
Drug: Low-gradient severe
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-gradient severe aortic stenosis with reduced stroke volume index (≤ 35 mL/m²)
Study: 16864815
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BTXA) 50 units/0.25 mL
Study: 16864815
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (0.25 mL)
Study: 12615873
Drug: Beta-lactam therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactam therapy (including cefuroxime and amoxicillin)
Study: 12615873
Drug: Beta-lactam therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-lactam therapy
Study: 10844622
Drug: Essential amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino acids (EAAs) 3.6 g three times daily with meals for three months
Study: 9228227
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with additional ultrasound treatment for 12 weeks (30 kHz continuous ultrasound 100 mW/cm2 three times a week)
Study: 9228227
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy with topical application of hydrocolloid dressings and compression therapy
Study: 1859751
Drug: Edrophonium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1.0 mg kg‐1
Study: 29334721
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) 8 mg/kg intravenously every 4 weeks
Study: 23546863
Drug: Transfixion and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfixion and excision of the sac in the traditional manner (Group L)
Study: 12445840
Drug: Low-dose prednisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisone (initial dose: 20 mg/day, maintenance dose: 10 mg/day)
Study: 1279928
Drug: Infusions of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusions of dextran-40 with pentoxifylline
Study: 1279928
Drug: Saline infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusions with pentoxifylline
Study: 1279928
Drug: Saline infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusions with placebo medication
Study: 6428171
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with verapamil (360 mg daily) and atenolol (100 mg daily)
Study: 6428171
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug therapy (either verapamil or atenolol)
Study: 3094443
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (1.5 g) with probenecid (1 g)
Study: 3094443
Drug: Amoxicillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (3 g) with probenecid (1 g)
Study: 31983031
Drug: Standard-of-care medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care medical treatment (control)
Study: 25707509
Drug: IgE antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgE antibodies to hazelnut components (Cor a 9 and Cor a 14)
Study: 30379222
Drug: Goal-directed therapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed therapy group
Study: 19415350
Drug: G-Cem (GC)
Normalized name: CEM-Urea
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Cem (GC)
Study: 18209581
Drug: PPI (rabeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI (rabeprazole, lansoprazole, or omeprazole) plus amoxicillin and metronidazole given b.i.d. for 7 days
Study: 17000910
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg/d and Placebo
Study: 14624763
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times weekly GH injections
Study: 14624763
Drug: Daily GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily GH injections
Study: 24477299
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g of ethanol/d as gin or beer
Study: 20570264
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol gel (0.06%)
Study: 20570264
Drug: Oral tibolone
Normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tibolone (2.5 mg)
Study: 16162191
Drug: Quality‐of‐Life Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality‐of‐Life Therapy (QOLT)
Study: 11076820
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg) and vitamin B(12) (1 mg) daily (n=59)
Study: 8805892
Drug: EMLA 1
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA 1 ml + GTN 2 mg
Study: 8805892
Drug: EMLA 2
Normalized name: Vyfemla 28 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA 2 ml + GTN 2 mg
Study: 8805892
Drug: EMLA 2
Normalized name: Vyfemla 28 Day Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA 2 ml only
Study: 1634449
Drug: Ibudilast (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibudilast (20 mg twice daily orally)
Study: 25804039
Drug: ET 90
Normalized name: Ferralet 90
DrugBank: Docusate (DB11089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET 90 mg four days or more a week
Study: 25804039
Drug: ET 90
Normalized name: Ferralet 90
DrugBank: Docusate (DB11089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ET 90 mg 3 days or less a week
Study: 22784436
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive behavioral therapy (n=200)
Study: 15377968
Drug: Practice group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practice group (serial administration of BESS)
Study: 15377968
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no serial administration of BESS)
Study: 2980956
Drug: Aspirin therapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin therapy (mean duration 357 days)
Study: 2980956
Drug: Non-aspirin NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-aspirin NSAID therapy (mean duration 67 days)
Study: 17298716
Drug: Vaginal capsules
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal capsules of 200 mg of micronized progesterone (Utrogestan), 3 times daily
Study: 17298716
Drug: Micronized progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized progesterone in gel (Crinone 8%), once daily
Study: 11350327
Drug: Isoflurane through
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane through the agent‐saving device
Study: 9542476
Drug: ABT-761 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-761 (50 to 200 mg/day)
Study: 8993088
Drug: Gepirone ER
Normalized name: gepirone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepirone ER (10‐60 mg/day)
Study: 8993088
Drug: Imipramine (50‐300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (50‐300 mg/day)
Study: 2400306
Drug: IOPL with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IOPL with saline solution
Study: 2400306
Drug: IOPL with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IOPL with saline solution and 2 g of chloramphenicol succinate
Study: 31385489
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic field (PEMF) therapy in addition to transcutaneous electrical nerve stimulation (TENS) and hot pack (HP) therapy
Study: 31385489
Drug: Sham magnetic
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham magnetic field (without current flow) in addition to TENS and HP therapy
Study: 25582795
Drug: Full participation
Normalized name: Full Marks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full participation group (treatment) in the extension programme
Study: 19054928
Drug: Sublingual-swallow immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual-swallow immunotherapy (SLIT) with a standardized Dermatophagoides pteronyssinus (D.p.)/D. farinae (D.f) 50/50 extract
Study: 9732884
Drug: Propafenone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (2 mg/kg)
Study: 9732884
Drug: Digoxin (0.007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin (0.007 mg/kg)
Study: 9732884
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (Propafenone vs Digoxin)
Study: 3338379
Drug: Educational group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational group meetings with NIDDM patients, consisting of three weekly lessons presented by a physician, nurse, and dietitian once every 4 months.